Coya Therapeutics, Inc. - COYA STOCK NEWS

Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company focused on enhancing regulatory T cell (Treg) function, has announced its participation in the Chardan 8th Annual Genetic Medicines Conference. The event will take place on September 30 – October 1, 2024, at the Westin Grand Central in New York City.

CEO Howard Berman, Ph.D. and Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D, will engage in a fireside chat on Tuesday, October 1, 2024, at 2:00pm ET. The discussion will be moderated by Keay Nakae, Senior Research Analyst at Chardan Capital Markets. Both executives will also be available for one-on-one meetings throughout the conference.

Coya Therapeutics (NASDAQ: COYA) announces promising results for COYA 302, a subcutaneously administered anti-inflammatory biologic, in a preclinical Parkinson's disease (PD) mouse model. The study shows that COYA 302 significantly reduces neuroinflammation in key brain regions affected by PD, including:

• Decreased microglial activation in the nigrostriatal pathway
• Reduced astrocyte numbers and activation (astrogliosis)

These findings suggest that COYA 302 can directly modulate brain inflammation when administered peripherally, potentially offering a new therapeutic approach for PD and other neurodegenerative diseases like Alzheimer's and Frontotemporal Dementia. The company plans to present or publish these results in a peer-reviewed setting.

Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on enhancing regulatory T cell function, announces CEO Howard Berman's participation in two upcoming healthcare conferences. On September 26, 2024, Dr. Berman will join a panel discussion at Munsch Hardt's 3rd Annual Texas Health Care Transactions Conference in Houston. On October 28, 2024, Dr. Berman and Dr. Stanley Appel will present data on COYA 302 at the inaugural Alzheimer's Drug Discovery Foundation (ADDF) Summit in Madrid, Spain.

The company will also present results from a Gates Foundation and Alzheimer's Association funded study on low-dose interleukin-2 in Alzheimer's patients at the Clinical Trials on Alzheimer's Disease conference. In May 2024, Coya received a $5 million strategic equity investment from ADDF to support COYA 302's development for Frontotemporal Dementia treatment.

Coya Therapeutics (NASDAQ: COYA) has announced a leadership transition, with Arun Swaminathan Ph.D. promoted to Chief Executive Officer effective November 1, 2024. Dr. Howard Berman, the company's founder, will transition to Executive Chair of the Board. Dr. Swaminathan, who joined Coya as Chief Business Officer in April 2023, has been instrumental in executing several significant commercial transactions, including Coya's recent $700 million licensing deal with Dr. Reddy's Laboratories.

The company is preparing for the release of Alzheimer's data at the CTAD24 conference on October 29, 2024, and continues to progress COYA 302 in ALS. Coya believes Dr. Swaminathan's experience will be valuable in advancing COYA 302 in related programs such as Frontotemporal Dementia, Parkinson's Disease, and other immune-mediated diseases.

Coya Therapeutics (Nasdaq: COYA) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:

1. Received a $5 million investment from the Alzheimer's Drug Discovery Foundation for COYA 302 development in Frontotemporal Dementia.

2. Obtained $3.85 million from Dr. Reddy's Laboratories for COYA 302's Phase 2 ALS trial.

3. Published promising Phase 1 results for CTLA4-Ig and IL-2 combination in ALS patients.

4. Expanded research collaboration with Houston Methodist Research Institute.

5. Filed new U.S. patents for COYA 301 in combination with GLP-1 receptor agonists.

6. Q2 2024 financials: $36.6 million cash on hand, R&D expenses of $4.6 million, and net loss of $2.9 million.

Coya Therapeutics (NASDAQ: COYA) has announced that results from a double-blind, placebo-controlled phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease will be presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid on October 29, 2024. The study, conducted at Houston Methodist Research Institute and supported by the Gates Foundation and Alzheimer's Association, evaluated 38 patients over 30 weeks. This presentation replaces the previously announced topline data release planned for Summer 2024. A prior open-label study showed that low-dose IL-2 was well-tolerated and resulted in significant improvements in cognitive function and regulatory T cell (Treg) function and numbers in AD patients.

Coya Therapeutics (NASDAQ: COYA) has filed for intellectual property protection for the combination of COYA 301 (low-dose interleukin-2) and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs). This combination aims to enhance regulatory T cell function and may offer a multi-pathway targeted approach for treating inflammatory diseases, including neurodegenerative, autoimmune, and metabolic conditions.

The company believes this proprietary combination could lead to value-creating business development partnerships and expand the GLP-1 market beyond diabetes and obesity. Data suggests the combination may have additive and/or synergistic anti-inflammatory effects on multiple cell types. Coya is investigating these combinations to potentially bring forward an optimized novel therapeutic approach for several diseases.

Coya Therapeutics has expanded its research collaboration with the Houston Methodist Research Institute (HMRI) to advance the development of regenerative T cell (Treg) exosome technology. This initiative is funded by the Johnson Center for Cellular Therapeutics and aims to progress towards a first-in-human clinical study. The collaboration will also focus on validating clinical biomarkers for neurodegenerative diseases and exploring drug combinations, particularly COYA 301 (low dose interleukin-2) and COYA 302 (LD IL-2 + CTLA4-Ig). These efforts could offer new therapeutic avenues for conditions like ALS, Alzheimer's, and Parkinson's Disease.

Coya Therapeutics has published a study in Frontiers in Neurology on an ALS treatment using a combination of CTLA4-Ig and Low Dose Interleukin-2. The treatment showed promising results in halting disease progression over 24 weeks and reducing inflammation and oxidative stress. Four participants were administered the treatment, which was well-tolerated with no serious adverse events. The study revealed an improvement or stability in ALSFRS-R scores and significant enhancement in Regulatory T cell function. The company plans to file an IND application with the FDA for a larger, randomized controlled trial.